In a significant advancement for heart failure treatment, new guidelines have been introduced to enhance early access to medical interventions for chronic heart failure, potentially saving lives and reducing hospital admissions across England. These updated recommendations aim to prevent approximately 3,000 deaths and 5,500 hospital admissions annually, marking a pivotal shift in the management of this pervasive condition.
Heart failure, particularly heart failure with reduced ejection fraction (HFrEF), poses a considerable challenge to healthcare systems. The updated guidelines recommend administering specific medications up to a year earlier than previously advised, thereby enabling patients to maintain a better quality of life for a longer period. This update builds on the clinical guideline first established in 2018, reflecting the evolving landscape of heart failure treatment.
The guidelines focus on four primary treatment types: angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors. The new approach allows for the concurrent use of these medications without waiting for the optimisation of any single drug, which traditionally could take over a year. Notably, SGLT2 inhibitors such as empagliflozin and dapagliflozin can now be prescribed at any stage in the treatment pathway, significantly broadening their accessibility.
Additionally, the use of angiotensin receptor neprilysin inhibitors (ARNIs) has been revised. These medications are now recommended for patients unable to tolerate ACEIs, expanding their use beyond those already stabilised on ACEIs or angiotensin receptor blockers (ARBs). This change, coupled with the ability for general practitioners to initiate both SGLT2 inhibitors and ARNIs with specialist advice, ensures faster access to these vital treatments.
Eric Power, deputy director in NICE’s Centre for Guidelines, emphasised the importance of these updates: “Heart failure is common, with approximately 614,000 adults in England living with a diagnosis. Although there is no cure, advances in treatment have significantly improved patient outcomes. This update allows us to swiftly incorporate emerging evidence, promoting wider access to effective treatments. The expected result is a profound impact on the lives of those with heart failure and a reduction in unplanned hospital visits.”
Heart failure with reduced ejection fraction occurs when the heart's left side is unable to pump blood effectively, a chronic condition impacting both survival rates and quality of life. Current statistics from the Office for National Statistics, alongside the NHS Quality and Outcomes Framework 2023-24, estimate that 63% of the 614,000 adults with heart failure in England suffer from HFrEF.
This development is part of a broader effort to improve outcomes for heart failure patients, providing healthcare professionals with the tools and guidelines necessary to deliver optimal care. As medical practices continue to advance, such updates are crucial to ensuring that patients receive the most effective treatments available.
For further resources and information on the updated guidelines, healthcare professionals and patients are encouraged to refer to the associated guidance on the pharmacological treatment of chronic heart failure. Additionally, subscribing to newsletters and alerts will ensure stakeholders remain informed about important developments from NICE.